Yesterday, March 9, 2016, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $6.95 to $910,998,000.00.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 613 shares at $5.76 on March 9, 2016. Following this transaction, the SVP, Human Resources owned 194,727 shares meaning that the stake was reduced by 0.31% with the 613-share transaction.

Gleeson Michael, who is SVP, North American Com. Ops. at GenMark Diagnostics, sold 559 shares at $5.76 on March 9, 2016. Following this transaction, the SVP, North American Com. Ops. owned 254,598 shares meaning that the stake was reduced by 0.22% with the 559-share transaction.

Stier Eric, who is SVP & General Counsel at GenMark Diagnostics, sold 266 shares at $5.76 on March 9, 2016. Following this transaction, the SVP & General Counsel owned 111,923 shares meaning that the stake was reduced by 0.24% with the 266-share transaction.

The shares most recently traded at $4.98, down $0.78, or 15.66% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares bought: 4,500
  • 4-Week # shares sold: 8,712
  • 12-Week # shares bought: 4,500
  • 12-Week # shares sold: 32,280
  • 24-Week # shares bought: 13,500
  • 24-Week # shares sold: 45,092

The average volume for GenMark Diagnostics has been 220,700 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $261.2 million and is part of the health care sector and health services industry. Shares are down 34.41% year-to-date as of the close of trading on Wednesday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, commercializes, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology. Currently, there are 5 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings

rates GenMark Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full

GenMark Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LKQ (LKQ) - FREE Research Report

Mcgarvie Blythe J, who is Director at LKQ, bought 3,000 shares at $30.31 on March 9, 2016. Following this transaction, the Director owned 19,808 shares meaning that the stake was boosted by 17.85% with the 3,000-share transaction.

The shares most recently traded at $30.16, down $0.15, or 0.51% since the insider transaction. Historical insider transactions for LKQ go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 1,070
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 13,542
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 13,542

The average volume for LKQ has been 1.8 million shares per day over the past 30 days. LKQ has a market cap of $9.3 billion and is part of the consumer goods sector and automotive industry. Shares are up 2.67% year-to-date as of the close of trading on Wednesday.

LKQ Corporation, together with its subsidiaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, and internationally. It operates in three segments: North America, Europe, and Specialty. The company has a P/E ratio of 22.0. Currently, there are 9 analysts who rate LKQ a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LKQ - FREE

TheStreet Quant Ratings

rates LKQ as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

LKQ Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Usana Health (USNA) - FREE Research Report

Gull Global Ltd, who is 10% Owner at Usana Health, sold 10,000 shares at $116.07 on March 9, 2016. Following this transaction, the 10% Owner owned 6.4 million shares meaning that the stake was reduced by 0.16% with the 10,000-share transaction.

The shares most recently traded at $113.36, down $2.71, or 2.39% since the insider transaction. Historical insider transactions for Usana Health go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 56,000

The average volume for Usana Health has been 143,700 shares per day over the past 30 days. Usana Health has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are down 9.66% year-to-date as of the close of trading on Wednesday.

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease worldwide. The company has a P/E ratio of 21.3. Currently, there are no analysts who rate Usana Health a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on USNA - FREE

TheStreet Quant Ratings

rates Usana Health as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Usana Health Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.